In this review:
4 years after stopping pembrolizumab in ipilimumab-naive advanced melanoma
5-year survival with pembrolizumab in advanced melanoma
Survival after CLND in melanoma with positive sentinel node
Encorafenib + binimetinib vs. vemurafenib or encorafenib in BRAF-mutant melanoma
Adding epacadostat to pembrolizumab in unresectable or metastatic melanoma
Adjuvant nivolumab vs. ipilimumab after complete resection of stage III/IV melanoma
Validation of AJCC melanoma staging system, 8th edition
A CD122-biased agonist + nivolumab in advanced solid tumours
Avelumab for metastatic, progressed Merkel cell carcinoma
Cemiplimab for metastatic cutaneous SCC
Please login below to download this issue (PDF)